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OBJECTIVES: To analyze the cost savings after an introduction of the generic version 
of azathioprin for patients with transplanted kidney. METHODS: Prospective obser-
vational study of the cost of pharmacotherapy of patients was performed during 
2009–2010. It was collected information for 121 patients previously treated with the 
originator and transferred to the generic medicines. The patient sample was system-
atized according to patient age, gender, additional medicines used for main therapy, 
and monthly cost of pharmacotherapy. RESULTS: The average monthly cost of the 
combined immunosuppressing therapy when the original product was included was 
c320.99 and after the introduction of the generic version it became c311.29. On the 
other hand the monthly cost of the therapy only with azathioprin changed from c6.71 
to c5.78 per patient per month. The patients’ number varies among 121 to 96 during 
different months due to the drop out. After the introduction of the generic version 7 
patients were switched to another immunosuppressive agent, while for the originator 
the corresponding ﬁ gure is 2 patients. For the switched patients the cost of pharma-
cotherapy did not increase. CONCLUSIONS: In spite of the contradictory introduc-
tion of generic versions of immunosuppressors, due to their narrow therapeutic index 
the drop out of the patients is not higher and the savings for the health care system 
are possible.
PUK11
A COST EVALUATION OF PERITONEAL DIALYSIS AND HEMODIALYSIS 
IN THE TREATMENT OF ESRD IN SÃO PAULO, BRAZIL
Ferraz MB1, Mendes de Abreu M2, Walker DR3, de Castro Cintra Sesso R1
1Universidade Federal de São Paulo, Sao Paulo, SP, Brazil; 2Universidade Federal de Sao 
Carlos, Sao Carlos, SP, Brazil; 3Baxter Healthcare Corporation, McGaw Park, IL, USA
OBJECTIVES: ESRD patient survival is similar for hemodialysis (HD) and peritoneal 
dialysis (PD). In Brazil, access to dialysis is universal, although the resources consumed 
and their costs are poorly understood. We compare the resources used for the treat-
ment of patients undergoing HD or PD who are covered by public insurance. 
METHODS: A one-year prospective study comparing resource use and total costs of 
prevalent patients treated with HD (n = 210) and PD (n = 194) was conducted in 5 
dialysis units in Sao Paulo, Brazil. Inclusion criteria: ≥18 years of age and clinically 
stable on chronic dialysis. The study period was April 2007 to February 2009. Data 
were obtained at baseline, 6 and 12 months using surveys and medical records. Cost 
categories included hospitalizations, diagnostic and therapeutic procedures, medica-
tions, professional fees, transportation, and lost productivity (current homemakers 
who stopped working due to dialysis). Government reimbursement rate was used as 
a proxy for the direct costs related to the act of dialysis (maintenance). The study took 
the societal perspective. RESULTS: Approximately 50% of HD and 48% of PD 
patients were female (p = 0.75); 54% and 58% were white (p = 0.48); mean age was 
55.2 and 60.6 (P < 0.001); 62% and 71% had diabetes (p = 0.0528); and 59% and 
55% had coronary heart disease (p = 0.37), respectively for HD and PD. Overall 
average costs per patient-year of follow up was US$23,283 for HD and US$23,285 
for PD patients. The average annual cost per patient-year, per category, for HD and 
PD were respectively, US$11,774 and US$14,058 for maintenance dialysis costs; 
US$9,208 and US$7,559 for medications; US$94 and US$43 for hospitalization, 
US$796 and US$487 for travel costs and $US323 and $264 for current homemakers 
lost income due to dialysis. CONCLUSIONS: Mean annual total cost of PD and HD 
are nearly identical, even though the former were signiﬁ cantly older and more 
diabetic.
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OBJECTIVES: Compared to dialysis, kidney transplantation is a highly cost-effective 
choice for most patients with ESRD. Post transplantation, a key objective is to main-
tain a functioning graft. When graft failure occurs, the majority of patients return to 
dialysis. This study is performed to assess the cost of renal graft failure in a UK setting. 
METHODS: A model was built using data from the UK renal registry (2007–2008) 
to estimate the number of graft failures occurring in the ﬁ rst year after transplantation. 
Costs for procurement, transplantation, and for the treatment of graft failure, were 
derived from the result of a systematic review. This study adopted an investment 
perspective—all the medical resource used from organ procurement to the treatment 
of graft failure were taken into consideration. RESULTS: In the UK, the cost of renal 
graft failure was approximately £58,847 when taking account the medical resource 
used from an investment point of view (including transplantation cost, immunosup-
pressive medication cost and resource to treat post transplantation adverse events for 
graft failure patients). The post graft failure cost was £28,179. The most important 
cost contributors are dialysis cost, transplantation cost and post transplantation 
immunosuppressive medication cost. CONCLUSIONS: Estimating the economic 
impact of graft loss should take into account the cost of management of patients post 
graft failure, as well as previous medical investment that is lost with the graft (includ-
ing costs associated with procurement of the organ and transplantation). Improve-
ments in the management of renal transplant patients are needed to reduce the risk 
of graft loss and the economic burden of graft failure to the health care system.
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OBJECTIVES: Acute urinary retention (AUR) is one of the most signiﬁ cant complica-
tions of long-term benign prostatic hyperplasia (BPH) and often leads to prostate 
surgery. AUR also represents an important and feared event that needs to be quantiﬁ ed 
from an economic perspective as well as from the viewpoint of BPH patients. 
METHODS: French hospital information program (PMSI) databases from 2005 to 
2008 were used to assess the number of hospitalizations for AUR and their manage-
ment among males ≥50 years old presenting with a diagnosis of BPH. Number of 
patients concerned and rates of re-hospitalizations and deaths due to AUR were 
estimated using the linking system of the PMSI. Cost estimation was performed for 
the year 2008 adopting the Sickness Funds perspective. RESULTS: During the 4-year 
period, AUR frequency increased to 38,914 hospitalizations (+20.5%, +8.2%, +1.2% 
compared with 2005, 2006 and 2007, respectively). In 2008, mean length of stay was 
5.5 ± 6.9 days and decreased of 6.6% within the study period. Proportion of stays 
referred by emergency department was 28.8% (14.1%, 20.6%, 25.3% in 2005, 2006 
and 2007, respectively). 26,581 males were concerned by at least one AUR (+15.4%, 
+5.9%, +0.0% compared with 2005, 2006 and 2007, respectively) of whom 32.6% 
were concerned by a recurrence (28.9%, 30.7%, 31.4% in 2005, 2006 and 2007, 
respectively). Mean age was 74.1 years (SD:10.4) (stable over the period) and 232 
patients (0.9%) deceased during their hospitalization in 2008. Mean cost per patient 
in 2008 was c2400 (c2663 vs. c1997 in public and private hospitals, respectively). 
Global cost of hospitalizations for RAU was estimated at c93.4 million (67.2% in 
public hospitals). CONCLUSIONS: AUR attributable to complicated BPH globally 
increased but tend to become stable in 2008. However, proportion of emergency 
utilization and recurrent stays ampliﬁ ed. Despite appropriate available therapies, 
prevention of BPH complications remains suboptimal.
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OBJECTIVES: Annual cost of renal replacement therapy is an important benchmark 
for public reimbursement of all health care services. The last report was presented 
more than 10 years ago in Hungary, so our objective was to calculate the current 
annual cost of waiting listed dialysis and renal transplantation. METHODS: We 
selected all waiting listed or renal transplanted patients between July 2004 and March 
2008. Resource utilization of all health care services with public reimbursement per 
patient in Q1 2008 were aggregated by linking claims records with anonimised patient 
IDs. We calculated health care costs of waiting listed and renal transplanted patients. 
Results were adjusted to gender, age and onset of ESRD by multivariate regression 
analysis. a total of 135 HUF/USD GDP speciﬁ c PPP exchange rate was employed to 
convert results into USD. 2008 cost calculations were compared to results of the 1997 
analysis. RESULTS: A total of 2209 patients were selected to the analysis. 3 year cost 
of waiting listed dialysis and renal transplantation was US$110,742 and US$87,420 
respectively. Renal transplantation is cost-saving within 2 years compared to dialysis. 
CONCLUSIONS: Between 1997 and 2008 the 3-year cost of waiting listed dialysis 
increased by 60.3%, 3-year cost of renal transplantation increased by 96,8% without 
correction for inﬂ ation. In real values the health care costs waiting listed dialysis and 
renal transplantation is reduced by 26.7% and 10,0%. During this period the cost-
containment measures of the National Health Insurance Fund were successful.
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OBJECTIVES: This study was conducted to identify and compare resources and costs 
used by dialysis patients in Belgium. METHODS: The records of 130 patients under-
going dialysis were retrospectively reviewed to identify direct medical and non-medical 
resources used over year 2006. Data collected: baseline medical characteristics, dial-
ysis-related information and resources used (hospitalizations, ambulatory care, medi-
cation, transport). Ofﬁ cial tariffs were used for costing. RESULTS: Patients were 
hospitalized 1.5 ± 1.7 times for 18.1 ± 29.1 days. Laboratory tests were performed 
more frequently in hemodialysis (HD) patients than in peritoneal dialysis (PD) patients 
(295.6 ± 137.7 vs. 120.1 ± 75.5; P < 0.0001). Patients on HD took more medications 
(12.4 ± 3.7 vs. 10.7 ± 4.3; P = 0.0254). 79% of patients received EPO (average dose: 
10,587 ± 14,114 IU). Patients on PD had more ambulatory consultations (9.7 ± 8.8 
